Gonzalez, M; Wengenmayer, P; Samoylenko, I; Ochsenreither, S; Richtig, E; Thomas, I; Erdmann, M; Lebbe, C; Martin-Liberal, J; Terheyden, P; Poltoratskiy, A; Sekacheva, M; Semiletova, Y; Eigentler, T; Schmitt-Bormann, B; Vahrenhorst, D; Kays, SK; Seibel, T; Quintini, G; Scheel, B; Falk, M; Gnad-Vogt, U; Codo, P.
IMMUNE PROFILING OF PATIENTS WITH ADVANCED MELANOMA INTRATUMORALLY TREATED WITH CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTIPD-1 ANTIBODIES - RESULTS OF A PHASE I TRIAL EXPANSION
J IMMUNOTHER CANCER. 2022; 10: A816-A816.-SITC 37th Annual Meeting (SITC 2022). ; Nov 8-12, 2022; Boston, USA.
Doi: 10.1136/jitc-2022-SITC2022.0784
[Poster]
Web of Science
FullText
FullText_MUG